4 results
Approved WMOCompleted
In this study, the main clinical hypothesis is that the TIMI clinically significant bleeding rates will not be different between the rivaroxaban and VKA treatment strategy groups at Month 12.
Approved WMOCompleted
Part 1: The primary objective is to investigate if the RNFL-ac in PD patients differs significantly from the RNFL-ac in healthy controls.Secondary Objectives are:1) to investigate if the RNFL-ac can be used to differentiate PD patients from healthy…
Approved WMOCompleted
To evaluate the safety and efficacy of PRX-102 in patients with Fabry disease currently treated with agalsidase alfa
Approved WMOCompleted
To evaluate the safety and efficacy of PRX-102 compared to agalsidase beta in Fabry disease patients with impaired renal function.